A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

NCT04129099 | Unknown Early Phase 1

• 1 other identifier: PGC0006
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 18 subjects to receive GC022F therapy.

Conditions

B-cell Acute Lymphoblastic Leukemia

Outcome Measures

Primary Outcomes (1)

• Incidence and severity of treatment related Adverse Events, CRS and Neurotoxicity (Safety and tolerability)

  Adverse events(AEs) will be collected and graded according to ASTCT consensus(for Cytokine Release Syndrome, CRS and Immune Effector Cell-Associated Neurotoxicity Syndrome, ICANS) and CTCAE v5.0(for AE except CRS/ICANS )

  2 years

Secondary Outcomes (3)

• CAR copies and concentration of GC022F in peripheral blood, bone marrow and CSF (amplification and persistence)

  2 years

• Overall response rate of patients who received GC022F infusion (efficacy)

  2 years

• Concentraiton of anti-GC022F antibody after infusion (humoral immune response)

  2 years

Study Arms (1)

CAR-T treatment group

EXPERIMENTAL

The patients will receive one dose of GC022F. GC022F dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg.

Biological: GC022F

Interventions

GC022F BIOLOGICAL

GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg.

CAR-T treatment group

Eligibility Criteria

• Age: 2 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 2-70 years;
• Eastern cooperative oncology group (ECOG) performance status of 0 to 2;
• Life expectancy≥12 weeks;
• CD19 and/or CD22 tumor expression demonstrated in bone marrow or peripheral blood by flow cytometry;
• Relapsed or refractory B- ALL: a) Refractory B- ALL: MRD≥0.1% or fail to achieve a CR after 2 cycles of a standard induction chemotherapy regimen or one-line/multi-line salvage chemotherapy; b) Relapsed B- ALL: Relapse after remission for the first time in 12 months or relapse after one-line/multi-line salvage chemotherapy; Relapse is defined as MRD≥0.1% or recurrence of primitive cell in peripheral blood or bone marrow(\>5%) after remission; c)Relapse after autologous stem cell transplantation or allogeneic hematopoietic stem cell transplantation; Relapse is defined as above; d)Patients with Philadelphia chromosome positive(Ph+) ALL were eligible if they were intolerant to or had failed two lines of tyrosine kinase inhibitor (TKI) therapy, or had t315i mutation.
• Did not receive hematopoietic stem cell transplantation≤6 months prior to enrollment;
• Adequate organ function defined as: a) Creatinine clearance (as estimated by Cockcroft Gault) \>60 mL/min; b) Serum ALT/AST \<2.5 ULN; c) Total bilirubin \<1.5 ULN (subjects with Gilbert's syndrome≤3 ULN); d) Cardiac ejection fraction≥50%, no evidence of clinically significant pericardial effusion as determined by an ECHO; e) No clinically significant pleural effusion; f) Baseline oxygen saturation \>92% on room air;
• Females of reproductive age must be in non-lactation period. Females of childbearing potential must have a negative serum or urine pregnancy test. All subjects must use medical-approved-contraception (such as intrauterine device and contraceptive drugs) during the period of trial and in 2 years after cell transfusion therapy; Males should avoid sperm donation;
• Venous access can be established, peripheral blood mononuclear cells (PBMC) can be collected in researcher's judgement;
• The subject agrees to and sign informed consent form, willing and able to comply with the planned visit, research, treatment planning, laboratory and other test procedures.

You may not qualify if:

• Isolated extra-medullary disease relapse;
• Central nervous system leukemia involved CNS-3;
• Concomitant malignancy other than cured non-melanoma skin cancer or cervical carcinoma in situ or localized prostate cancer or superficial bladder cancer or ductal carcinoma in situ or diagnosis of other malignancy exceeds 5 years without relapse or treatment during the 5 years;
• Any result of the following virology tests is positive: HIV; HCV; HBsAg; or HBCAb positive with HBV DNA copies positive; TPPA;
• Live vaccine ≤4 weeks prior to enrollment;
• For Ph+ ALL, TKI therapy ≤1 weeks prior to enrollment;
• Presence of ≥ grade 2 acute graft-versus-host disease (GVHD, Glucksberg criteria) or extensive chronic GVHD (Seattle criteria) that require treatment ≤4 weeks prior to enrollment, or during the study period the subject is required to receive anti- GCHD therapy in researcher's judgement;
• Presence of concomitant disease that require systemic steroids or other immune suppressive therapy during the study period in researcher's judgement;
• Allogeneic cell therapy (such as donor lymphocyte infusion, DLI) ≤4 weeks prior to enrollment;
• CNS stereotactic radiotherapy ≤4 weeks prior to enrollment;
• Toxicities related to previous therapy did not relieved to ≤1 grade, except hematological toxicity and alopecia;
• Known life-threatening hypersensitivity to cyclophosphamide or fludarabine, or presence of other intolerant conditions, or severe allergic constitution;
• Patients with active autoimmune disease (e.g., systemic lupus erythematosus, sjogren syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Hashimoto's thyroiditis, hypothyroidism which can be controlled by thyroid hormone replacement therapy is an exception);
• For patients that underwent or plan to undergo major surgical operation before CAR-T treatment, surgical operation happened ≤4 weeks prior to enrollment, or did not be fully recovered and clinically stable prior to enrollment, or be anticipated to undergo major surgical operation during the study;
• Any unstable cardiovascular diseases happened ≤6 months prior to enrollment, including but not limited to, unstable angina, myocardial infarction, heart failure (NYHA grade≥ III grade), severe arrhythmia that require drug interference, cardiac angioplasty/coronary stent implantation/ cardiac bypass surgery ≤6 months prior to enrollment;

Sponsors & Collaborators

• Hebei Yanda Ludaopei Hospital: lead
• Gracell Biotechnology Ltd.: collaborator
• Beijing Lu Daopei Hospital: collaborator

Study Sites (1)

Hebei Yanda Ludaopei Hospital

Sanhe, Hebei, 065200, China

RECRUITING

MeSH Terms

Conditions

Burkitt Lymphoma

Condition Hierarchy (Ancestors)

Epstein-Barr Virus Infections; Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections; Tumor Virus Infections; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Junfang Yang, Bachelor

  Hebei Yanda Ludaopei Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Junfang Yang, Bachelor

CONTACT

13522084342; Yangjunfang77@163.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 15, 2019
• First Posted: October 16, 2019
• Study Start: October 22, 2019
• Primary Completion: September 1, 2020
• Study Completion: June 1, 2022
• Last Updated: May 28, 2020

Record last verified: 2020-05

Locations

CN (1)